Business
DECN'S GenViro!(TM) Corona Virus "Swift" Kit, Now to Be Additionally Offered to Commercial Labs and Religious Groups as 12 Month Forecast is Raised to 525MM
DECN'S GenViro!(TM) Corona Virus "Swift" Kit, Now to Be Additionally Offered to Commercial Labs and Religious Groups as 12 Month Forecast is Raised to 525MM.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"RESPONSE FROM MEDICAL/HEALTHCARE ENTITIES & WHOLESALERS HAS BEEN CRUSHING AS GROUPS QUEUE UP FOR COVID-19 "SWIFT" KIT WHILE WE AWAIT FDA EMERGENCY APPROVALLOS ANGELES, CA / ACCESSWIRE / March 17, 2020 / Decision Diagnostics Corp. (OTCPINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, its GenAccord! systems for the uninsured and under-insured, its GenChoice! ("Ladybug") test strip now in the later stages of FDA 510(k) prosecution, and its GenUltimate Precis! products manufactured for International markets.Today, in this second of four updates about our GenViro™ Swift" kit for the testing of COVID-19, we will focus on our expected roll-out. We are happy to inform all interested parties that we have raised our 12-month forecast to 525 million kits. We have also added commercial laboratories, those labs with remote blood drawing stations (an estimated 27,000 nationwide), and religious groups to those entities that will receive the first kits manufactured post FDA Emergency Approval. These additional groups join chain pharmacies and grocers with pharmacies, clinics, home health service providers, and medical group practices as the first to receive our GenViro™ kits.Keith Berman, CEO of DECN commented, "Our first roll-out of 150,000 GenViro™ kits in the US and Canada will be paired with a roll-out of 100,000 GenViro™ kits in the EU. The first kits manufactured will be provided, free of charge or at a nominal fee, to professional entities. These groups include chain pharmacies and grocery store pharmacies, commercial laboratories with remote blood drawing stations, churches and other places of worship, as well as clinics and long term care facilities. Ultimately, GenViro™ will be sold directly to consumers, as our roll-out progresses."Mr. Berman continued, "Over the weekend, and after receiving a plan from our technical and R&D director, we decided to take the next step with GenViro™and further refine its use for hospitals. While we have not yet forecast sales to hospitals, and while most of the lesser...